Trial Profile
BOTOX in the treatment of urinary incontinence due to neurogenic detrusor overactivity in patients 3 months - 17 years
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2018
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Neurogenic bladder
- Focus Adverse reactions; Therapeutic Use
- Acronyms Botox treatment
- 22 Jun 2018 Status changed from not stated to discontinued.
- 09 Oct 2017 New trial record